Related references
Note: Only part of the references are listed.Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer
Andrew S. McDaniel et al.
BJU INTERNATIONAL (2017)
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer
Nicholas J. Vogelzang et al.
EUROPEAN UROLOGY (2017)
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
Howard I. Scher et al.
CANCER RESEARCH (2017)
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
David Lorente et al.
EUROPEAN UROLOGY (2016)
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents
M. Crespo et al.
BRITISH JOURNAL OF CANCER (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Targeting the adaptive molecular landscape of castration-resistant prostate cancer
Alexander W. Wyatt et al.
EMBO MOLECULAR MEDICINE (2015)
Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy
M. Thalgott et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer
Rhonda L. Bitting et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
The detection of EpCAM+ and EpCAM- circulating tumor cells
Sanne de Wit et al.
SCIENTIFIC REPORTS (2015)
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
Amir Goldkorn et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study
Matthew R. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man
Naomi L. Sharma et al.
CANCER CELL (2013)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2013)
Detection of circulating tumor cells in different stages of prostate cancer
Mark Thalgott et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate
Daniel C. Danila et al.
EUROPEAN UROLOGY (2011)
Characterising the castration-resistant prostate cancer population: a systematic review
M. Kirby et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D. Olmos et al.
ANNALS OF ONCOLOGY (2009)
Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors
Oscar B. Goodman et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Howard I. Scher et al.
LANCET ONCOLOGY (2009)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Steven J. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
Daniel C. Danila et al.
CLINICAL CANCER RESEARCH (2007)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
